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Abstract
Background: Chondrosarcoma responds poorly to adjuvant therapy and new, clinically relevant animal models are 
required to test targeted therapy.
Methods: Two human chondrosarcoma cell lines, JJ012 and FS090, were evaluated for proliferation, colony formation, 
invasion, angiogenesis and osteoclastogenesis. Cell lines were also investigated for VEGF, MMP-2, MMP-9, and RECK 
expression. JJ012 and FS090 were injected separately into the mouse tibia intramedullary canal or tibial periosteum. 
Animal limbs were measured, and x-rayed for evidence of tumour take and progression. Tibias and lungs were 
harvested to determine the presence of tumour and lung metastases.
Results: JJ012 demonstrated significantly higher proliferative capacity, invasion, and colony formation in collagen I gel. 
JJ012 conditioned medium stimulated endothelial tube formation and osteoclastogenesis with a greater potency than 
FS090 conditioned medium, perhaps related to the effects of VEGF and MMP-9. In vivo, tumours formed in intratibial 
and periosteal groups injected with JJ012, however no mice injected with FS090 developed tumours. JJ012 periosteal 
tumours grew to 3 times the non-injected limb size by 7 weeks, whereas intratibial injected limbs required 10 weeks to 
achieve a similar tumour size. Sectioned tumour tissue demonstrated features of grade III chondrosarcoma. All JJ012 
periosteal tumours (5/5) resulted in lung micro-metastases, while only 2/4 JJ012 intratibial tumours demonstrated 
metastases.
Conclusions: The established JJ012 models replicate the site, morphology, and many behavioural characteristics of 
human chondrosarcoma. Local tumour invasion of bone and spontaneous lung metastasis offer valuable assessment 
tools to test the potential of novel agents for future chondrosarcoma therapy.
Background
Chondrosarcoma is a common primary bone sarcoma,
which is second only to osteosarcoma in incidence. It
most often arises in the over 40 age group [1], and is asso-
ciated with significant mortality and morbidity [2,3].
Although a significant proportion of chondrosarcomas
are low-grade, these are well-known to recur locally, even
5 years or more following the initial tumour resection.
This often requires further wide-margin surgery, with the
potential for significant morbidity [4].
One of the key problems in chondrosarcoma, giving
rise to poor patient outcomes, is the cancer's lack of
response to both chemotherapy [5] and radiotherapy [6],
leaving surgery as the only treatment option. Although
the reasons for this are yet to be fully defined, it is
thought that a variety of factors are contributory, includ-
ing p-glycoprotein expression [7].
A more in-depth understanding of chondrosarcoma
biology will hopefully lead to new molecular agents
which can target the pathways responsible for chondro-
sarcoma progression. However, in order to achieve this
goal, more appropriate animal models using human
chondrosarcoma cells are required as a means to rigor-
ously test candidate molecular agents.
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chondrosarcoma models available, which utilise both ani-
mal and human chondrosarcoma cell lines [8]. Most of
the recently described models involve subcutaneous
implantation of cells which lacks pathogenic relevance to
the human disease. There is one recently described
model implanting human chondrosarcoma in the mouse
skull [9], and while this is orthotopic, the skull is an
uncommon site for chondrosarcoma [10]. This model is
also technically demanding which limits widespread use.
Consequently, new orthotopic models are required. Our
laboratory has previously developed an intratibial mouse
model of human osteosarcoma using the non-trans-
formed, SaOS-2 cell line [11]. This has led to successful
evaluation of novel agents such as PEDF [12], the
DNAzyme Dz13 [13], which downregulates c-jun, and
also uPAR DNAzyme [14]. Given that an endosteal,
appendicular location is most common for chondrosar-
coma in human patients [2], a similar approach in the
mouse would benefit research of similar agents in chond-
rosarcoma.
The aim of this study was to develop new orthotopic
models of human chondrosarcoma in the nude mouse,
replicating intermediate to high-grade chondrosarcoma
or low-grade chondrosarcoma. These models could then
serve as a platform for testing of candidate drug mole-




JJ012 and FS090 cells were provided by J.A Block, (Rush
University Medical Centre, Chicago, USA). Cells were
cultured in DMEM (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal calf serum (FCS) and 1% antimi-
crobials, and were removed from 75 ml culture flasks by
incubating in 2 ml of trypsin/EDTA with type I collage-
nase (1 mg/ml) (Sigma-Aldrich, Australia) at 37°C for 5
minutes. To compare cell morphology, JJ012 and FS090
cells were grown to 70% confluence on 6 well plates, fixed
in methanol and then stained with hematoxylin and
eosin. Chondrosarcoma cell-conditioned media was har-
vested after exposure to cells (JJ012 or FS090) at 80% con-
fluence for 48 h under the conditions described. Media
was used for the HMEC-1 tube formation and osteoclas-
togenesis assays described below. HMEC-1 cells (Centre
for Disease Control, Atlanta, GA) were cultured in
MCDB131 medium (Invitrogen, Carlsbad, CA) supple-
mented with 10 ng/ml of epidermal growth factor
(Sigma-Aldrich, Australia), and 1 μg/ml hydrocortisone
(Sigma-Aldrich, Australia). The mouse monocyte cell
line, RAW 246.7 (donated by Prof T.J. Martin, St Vincent's
Institute, Melbourne, Australia), was grown in α-MEM
(Invitrogen, Carlsbad, CA) supplemented with 10% FCS
and 1% antimicrobials.
Proliferation assay
JJ012 or FS090 cells were seeded in 96 well plates, with
5000 cells/well and 3 repeats used for each cell line and
time point. At day 2 and day 4, cells were fixed in metha-
nol, stained with propidium iodide (1:10,000) and the
central field of each well was visualised at ×40 magnifica-
tion using a Nikon Eclipse TE2000-U microscope (Nikon,
Australia), and photographed with a SPOT Advanced
camera and software (Diagnostic Instruments Inc., Ster-
ling Heights, MI). Cells fluorescing red under a Y-2E/C
filter were counted using Image J software (National
Institutes of Health, USA).
Invasion assay
The invasion assay was based on Dass et al. [11] with
minor modifications. Boyden chamber inserts with 8 μm
filter membranes (BD Biosciences, Australia) were coated
with a 50 μl volume of 25% Matrigel/75% Opti-MEM
(Invitrogen, Carlsbad, CA) and incubated at 37°C for 30
min in companion plates. JJ012 and FS090 cells were
trypsinised, centrifuged and washed in 5 ml of OptiMEM
to remove excess serum, then further centrifuged and
resuspended in low serum medium (LSM) containing
0.5% FCS. 5 × 104 cells in 0.2 ml LSM volume were added
to the Boyden chambers in triplicate. 0.8 ml of α-MEM
with 10% FCS was added to each well to create a concen-
tration gradient. The plate was incubated for 24 h at 37°C
in 5% CO2 and then invading cells were stained with
Quick-Dip (Froline, Sydney, Australia). The central
region of each membrane was photographed at × 200
magnification and cells were counted manually.
Colony formation assay
This was based on a method by Luu et al [15]. Briefly,
wells of a 24-well plate were coated with type I collagen
(BD Biosciences, Australia) at a concentration of 1.69 mg/
ml in 2× α-MEM, supplemented with 20% FCS and 0.75%
NaHCO3. To each well, a top layer of collagen I gel, con-
taining 2000 suspended JJ012 or FS090 was added. Colo-
nies greater than 10 cells were counted at day 5.
Tube formation assay
2.5 × 104 HMEC-1 cells were incubated in 100 μL of har-
vested cell-conditioned medium, either from JJ012 or
FS090, in wells of a 96-well plate (4 repeats), coated with
100 μL of 100% Matrigel (BD Biosciences, Australia).
Images were acquired of HMEC-1 tube-like structures at
8 h, and the total number of tube structures was manually
counted for each well. Apart from using conditioned cell
medium from chondrosarcoma cell lines, this assay was
based on that described by Phung and Dass [16].
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For conditioned media assays, RAW 246.7 cells were
plated at a density of 1.3 × 104/well in a 96 well plate with
α-MEM containing 10% FCS on day 0. On day 1, media
was changed to harvested cell-conditioned media (from
either JJ012 or FS090) containing 100 ng/ml rhRANKL (R
& D Systems, Minneapolis, MN) and 10% fetal calf
serum. On day 4, cells were fixed with 25% citrate, 56%
acetone and 3% formaldehyde for 30 s at 37°C, and then
stained with 200 μl of TRAP stain for 1 h at 37°C accord-
ing to the manufacturer's protocol (Sigma-Aldrich, Aus-
tralia). Cells were then washed in tap water, and lightly
counterstained in hematoxylin. The number of positively-
staining osteoclast-like cells were counted manually. For
co-culture assays, JJ012, or FS090 cells were plated at a
density of 1.0 × 104/well in 96 well plates on day 0, and
then on day 1 RAW 246.7 cells were seeded at 1.3 × 104/
well in media supplemented with 100 ng/ml rhRANK.
On day 4 cells were fixed and stained with TRAP as
described above. Control wells, containing 1.3 × 104 RAW
246.7 cells/well in media supplemented with 100 ng/ml
rhRANKL on day 1 were used for comparison of osteo-
clastogenic potential.
Western blotting
Equal cell numbers of JJ012 and FS090 were grown to 90%
confluence and then total cell protein was extracted from
cells with RIPA buffer (150 nM NaCl, 50 nM Tris pH 8.0,
1 mM EDTA, 0.1% SDS, and 1% Triton X-100) and a
complete mini protease inhibitor cocktail (Roche, Man-
nheim, Germany). Samples, combined with NuPAGE
LDS sample buffer (Invitrogen, Australia), were separated
on 4-12% Bis-Tris NuPAGE gels (Invitrogen, Australia)
and transferred to PVDF membranes (Invitrogen, USA).
Antibodies to human VEGF, GAPDH (Santa Cruz Bio-
technology, Santa Cruz, CA), and also RECK (R & D Sys-
tems, Minneapolis, MN) were applied. Bands were
visualized using secondary antibodies conjugated with
HRP and a chemiluminescent kit (ECL detection reagent,
Amersham Pharmacia Biotech Australia).
Gelatin zymography
JJ012 and FS090 cells were grown to 80% confluence and
then washed in PBS and immersed in serum-free
medium for 24 h. Medium was then harvested and centri-
fuged at 400 g for 5 min. Equal quantities of protein con-
firmed on protein assay (Pierce Biotechnology, Rockford,
IL) were loaded onto Novex 10% gelatin gels (Invitrogen,
Australia). Recombinant human MMP-2 and MMP-9 (R
& D Systems, Minneapolis, MN) were loaded as positive
controls. Following electrophoresis, gels were incubated
in renaturing and developing buffers (Invitrogen, Austra-
lia), stained with 0.1% Coomassie brilliant blue and
destained in 7.5% acetic acid and 10% ethanol. Gel images
were obtained with a Bio-rad Universal Hood II, and
Quantity One software (Bio-rad, Australia).
In vivo methods
Animal experimentation was approved by St Vincent's
Hospital Animal Ethics Committee. Female, 5-week old
Balb/c nude mice were anaesthetised with ketamine (100
mg/kg) and xylazine (10 mg/kg). 2 × 104 JJ012 or FS090
cells were suspended in 10 μL of 50% Matrigel/PBS, and
injected into the intramedullary canal of the left tibia (n =
5 per study group) or into the periosteum of the anterior
tibia (n = 5 per study group). Cells were checked for via-
bility using trypan blue exclusion prior to injection. Tis-
sue volume around the proximal tibia was measured at
weekly intervals with calipers in the mediolateral and
anteroposterior planes [17] and expressed as a ratio of the
injected to the non-injected limb. Tibial radiographs were
taken at 35 kV using a cabinet system (FaxitronCorp.,
McMinnville, OR). After fixing in 4% paraformaldehyde,
and decalcifying in 0.4 M EDTA/PBS, limbs were pro-
cessed and embedded in paraffin, sectioned at 5 μm, and
stained with hematoxylin and eosin. Formalin-fixed, par-
affin-embedded lungs were sectioned at 5 μm, and 40
sections from the middle third of each lung were evalu-
ated for metastases. In two limbs containing periosteal
JJ012 tumours, TRAP staining was performed to detect
the presence of osteoclasts. Tissue sections were de-par-
affinised, rehydrated in an ethanol series, stained with
TRAP (Sigma-Aldrich, Australia) for 1 h at 37°C, rinsed
in tap water, lightly counterstained in hematoxylin and
then mounted in 50% glycerol.
Statistical analyses
Statistical significance was determined for both in vitro
and in vivo data using a one-tailed Student's t-test. P val-
ues < 0.05 were considered significant.
Results
Cell morphology
JJ012 and FS090 cells stained with hematoxylin and eosin
were found to demonstrate different morphological fea-
tures. JJ012 were generally polyhedral in shape, with vari-
able, ovoid nuclei and prominent nucleoli (Fig.1a). JJ012
cells lacked polarity in contrast with FS090, which were
more spindle-shaped, and had less pleomorphic nuclei
(Fig.1b).
Proliferation assay
Overall, JJ012 demonstrated more aggressive behaviour
in vitro. At day 2 and day 4 the average cell count for JJ012
was 1876 and 4155 respectively, versus 1521 and 2433 for
FS090 (p = 0.017 at day 2, and p = 0.010 at day 4) (Fig.1c).
From these average cell counts, the doubling time for
JJ012 was calculated at 39.5 h versus 80 h for FS090.
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To further investigate proliferation in a matrix replicating
bone, a collagen I colony formation assay was performed.
JJ012 cells readily formed colonies by day 5 in collagen I
gel (Fig.1d). By contrast FS090 showed no evidence of
colony formation in collagen I (Fig.1e).
Invasion assay
Invasion of matrix also predicts tumour progression, and
at day 2 post seeding of 40,000 cells per Boyden chamber,
an average number of 813 JJ012 cells were found to have
invaded the Matrigel, versus 141 FS090 cells (p = 0.0005)
(Fig.2a).
Gelatin zymography
In an attempt to explain the differences in invasive capac-
ity, cell-conditioned medium was analysed for gelatinase
activity. Harvested medium from JJ012 was positive for
pro MMP-9 but not pro or activated MMP-2, whereas
FS090 medium yielded no detectable gelatinase bands
(Fig.2b). MMP-2 and MMP-9 are important facilitators of
cell invasion, and therefore the absence of these enzymes
in FS090 is likely to explain the marked difference
observed in the Matrigel invasion assay and also a lack of
tumorigenesis.
Angiogenesis assay and associated protein markers
Cell-conditioned medium from JJ012 stimulated HMEC-
1 cells to form an average number of 64.5 tubes versus
43.8 for FS090 media (p = 0.007) (Fig.3a). The FS090 cul-
tured medium was less angiogenic and this corresponded
with virtually absent expression of VEGF on western
blotting, in contrast with JJ012. FS090, on the other hand,
produced significantly higher levels of RECK protein
compared with JJ012 (Fig.3b), and this protein is known
to inhibit MMP-2, MMP-9 [18], and possibly also VEGF
[19], which may explain the absence of these target pro-
teins in FS090.
Figure 2 Chondrosarcoma cell invasion. a) A higher number of 
JJ012 cells invaded Matrigel compared with FS090 (* p < 0.05). b) 
Greater invasive capacity corresponded with the presence of pro 
MMP-9 in JJ012 conditioned media on gelatin zymography. This was in 
contrast with undetectable pro MMP-9 in FS090. No MMP-2 was de-
tected for either cell line and no activated forms were present.
Figure 1 Chondrosarcoma cell morphology and proliferation. a) 
JJ012 demonstrated high pleomorphism and nuclear atypia with 
prominent nucleoli. b) FS090 had more distinct polarity and less nucle-
ar atypia. c) JJ012 proliferated at a higher rate than FS090 (*p < 0.05). d) 
Prominent colony formation was noted for JJ012 suspended in colla-
gen I gel. e) FS090 did not form colonies after 5 days.
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JJ012 cells implanted within the periosteum developed
into tumours by 4 weeks, while intratibial implanted
JJ012 cells developed tumours between 6-7 weeks
(Fig.4a). The average volume of JJ012 periosteal tumours
was 174.2 mm3 just prior to euthanasia at 7 weeks. Intrat-
ibial JJ012 tumours had an average volume of 198.5 mm3
just prior to euthanasia at 10 weeks. By contrast, FS090
implanted either within periosteum or within the
intramedullary canal did not form any tumours, even at 3
months (Fig.4a). Periosteal JJ012 tumours tended to
expand into the soft tissues in one part of the limb, while
intratibial tumours grew in a more circumferential man-
ner (Fig.4b). At dissection, new vessels arising from the
femoral artery and supplying the tumours were noted,
and corresponding with the in vitro angiogenesis activity
noted for JJ012. On sectioning of the proximal tibias,
tumour tissue invaded the cortex and medulla of the
metaphysis, while the epiphysis was largely preserved,
consistent with the human disease (Fig.4b). Radiolucen-
cies and opacities consistent with bony erosions and
periosteal reactions respectively were found on x-ray
(Fig.4b). All JJ012 periosteal tumours (5/5 animals)
resulted in spontaneous lung metastases by 7 weeks while
JJ012 intratibial tumours gave rise to lung metastases in
50% of animals (2/4) (Fig.4c). One of the original 5 ani-
mals in this latter group had been euthanised and
excluded from the study due to systemic infection at week
6. Metastases were only visualised on microscopy (rather
than macroscopically), and stained positive with Alizarin
red, indicating calcification, which is also characteristic of
human chondrosarcoma metastases (Fig.4d).
Tumour histology and influence on osteoclasts
JJ012 histology (either intratibial or periosteal) demon-
strated an undifferentiated, high-grade appearance
(Fig.5a) with pleomorphism and frequent nucleoli similar
to a patient biopsy sample of dedifferentiated chondro-
sarcoma (Fig.5b). The main difference noted in the ani-
mal model was the addition of a spindle cell population of
cells. TRAP staining of the JJ012 tumour tissue revealed
TRAP-positive, osteoclast-like cells at the bone-tumour
interface, which were associated with erosions of the cor-
tex (Fig.5c). There were none of these cells in the cortex
when tumour was not adjacent. These TRAP-positive
cells were thought to be osteoclasts activated by the adja-
cent tumour.
Influence of chondrosarcoma cell lines on osteoclasts
An osteoclastogenesis assay was then performed to quan-
tify the influence of chondrosarcoma cells over osteoclast
formation. Culture medium conditioned by either JJ012
or FS090 cells for 48 h was harvested and incubated with
the osteoclast precursor cell line RAW 264.7. JJ012 media
induced a significantly higher number of osteoclast-like
cells (average of 37) in comparison with FS090 which
resulted in an average of only 19 cells (p = 0.00035)
(Fig.5d). A similar pattern was noted when the chondro-
sarcoma cell lines were co-cultured with RAW 264.7, and
in this case JJ012 cells stimulated an average of 49 osteo-
Figure 3 Chondrosarcoma angiogenesis. a) Conditioned media 
from JJ012 induced a higher number of tube formations compared 
with FS090 (* p < 0.05). b) Greater angiogenic capacity in JJ012 corre-
sponded with the presence of VEGF on western blotting, in compari-
son with virtually undetectable VEGF in FS090. The anti-angiogenic 
protein RECK was prominently expressed by FS090, but not by JJ012.
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Figure 4 In vivo growth and progression of chondrosarcoma cell lines. a) This graph plots the injected to non-injected limb volume ratios for the 
study groups at each time point. Periosteal injected JJ012 developed into tumours most rapidly, followed 2-3 weeks later by intratibial injected JJ012. 
FS090 did not form tumours in either implantation site. b) Periosteal tumours expanded one area of the limb while intratibial tumours grew in a cir-
cumferential manner. On histology both tumours (T) invaded cortex, but leaving the epiphysis (E) largely intact. On radiographs, lytic regions (black 
arrow), and sclerotic (grey arrow) were noted in both models. c) 5/5 animals injected with periosteal JJ012 demonstrated lung metastases, in contrast 
with 2/4 animals in the intratibial group. d) Lung metastases (M) were lobular in appearance, and were positive on Alizarin red staining (arrows), indi-
cating calcification.
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medium with RANKL stimulated an average of 6 osteo-
clasts. These results indicated that cell interactions and
secreted humoral factors, by JJ012 in particular, were
capable of significantly increasing the number of osteo-
clasts formed, which might aid bone resorption and
tumour progression in vivo.
Discussion
To our knowledge, these described models are the first
clinically relevant orthotopic animal models of human
chondrosarcoma. This is because they utilise a non-trans-
formed human chondrosarcoma cell line, implanted into
the native medullary or periosteal environment and con-
sistently give rise to chondrosarcomas resulting in spon-
taneous lung metastases. Thus, the usual sequence of
human chondrosarcoma progression is replicated,
through proliferation, angiogenesis, invasion of cortical
bone and soft tissues, and blood borne metastasis to the
lung.
Of the seven most recently described chondrosarcoma
xenograft models, involving human chondrosarcoma cell
lines, only one was implanted into bone [9], albeit the
cranium. The majority of chondrosarcoma animal mod-
els are subcutaneous in the back or flank and none of
these human cell line models describe metastasis [8].
This could relate to a lack of metastases arising from
these subcutaneous sites, or else due to the implanted
cells being relatively indolent. The latter explanation is
quite possible given that at least two of these models
demonstrated features of intermediate grade histology
with obvious chondroid matrix production [20,21].
Of the nine published allograft models using animal-
derived chondrosarcoma, which are now infrequently
employed, only two involve intramedullary tumour
growth [22,23], and of these, only one model specifies
lung metastases, occurring in 1/24 rats implanted [22].
Tumours in this aforementioned study were also
described as well-differentiated, which is perhaps why
metastasis occurred in only one animal.
Transgenic chondrosarcoma models have also been uti-
lised with some success. Ho and colleagues have recently
described a mouse model of transgenic enchondromato-
sis expressing Gli2 and further modified, via heterozy-
gous knockout of p53, to produce low grade
chondrosarcomas in 50% of animals [24]. Likwise, c-fos
expression has been used to induce chondrosarcomas in
around half of animals tested, with a mean latency of 9.5
months [25]. While these transgenic models can mimic
the pathogenesis of human chondrosarcoma to some
extent, their relatively inconsistent tumour growth
reduces their power to test novel agents at this stage.
In relation to tumorigenic potential, significant differ-
ences in cell behaviour were identified between the two
cell lines, JJ012 and FS090, examined by this study.
Although both were derived from intermediate grade
chondrosarcoma, JJ012 has less defined cytoplasmic
polarity in contrast to the more spindle-shaped FS090,
and possesses larger nuclei with frequent nucleoli. The
Figure 5 Tumour histology and osteoclast involvement. a) Pleo-
morphic, ovoid cells (*) with an additional spindle cell population (ar-
rows) were noted for JJ012 tumours. b) Dedifferentiated 
chondrosarcoma from a human de novo tumour demonstrated some 
similar ovoid cells without a spindle cell component. c) In periosteal 
and intratibial tumours, TRAP staining (arrows) revealed prominent os-
teoclasts at the interface between tumour (T) and bone cortex (C), and 
this was associated with bone matrix erosion and a mass of dead cel-
lular material (D). d) An osteoclastogenesis assay demonstrated higher 
osteoclasts formed by JJ012 media (CM) compared with FS090 media 
(CM) (* p < 0.05), and the same relationship for chondrosarcoma and 
mouse monocyte (RAW 246.7) co-culture (* p < 0.05).
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flow cytometry analysis and identified JJ012 as being hyp-
oploid and the majority of FS090 being diploid [26].
Mankin and colleagues [27] demonstrated a strong asso-
ciation between ploidy and disease stage in musculoskel-
etal tumours, with the majority of benign tumours
diploid, and the majority of stage III tumours aneuoploid.
As previously noted, JJ012 is reported to have a consistent
chromosome 9 monosomy, and this is significant given
that a number of important tumour suppressor genes
occupy this locus, including INK4A/ARF [28], PTCH1
[29], and the more recently described RECK gene which
is downregulated in many common cancers [30,31].
A more recent study has attempted to define JJ012 and
FS090 on the basis of differentiation, and the pattern of
collagen markers suggests FS090 is the more differenti-
ated cell line [32]. However, other comparisons of cell
behaviour, including the influence on angiogenesis and
osteoclastogenesis have not previously been performed
for either cell line to our knowledge. This characterisa-
tion, in the present study, has provided a better under-
standing of each cell line's properties and explains the
dramatic difference in tumorigenesis.
An increased cell proliferation rate for JJ012 corre-
sponded with its more dedifferentiated morphology and
prominent nucleoli. This, combined with the high pro-
pensity to form colonies in collagen I matrix (a measure
of anchorage-independent growth), indicated strong
potential for tumorigenesis within a bone environment
[15]. Prominent anchorage-independent growth in JJ012
is likely related to its expression of anti-apoptosis pro-
teins Bcl-2, Bcl-xL and XIAP [33]. On the other hand, the
complete lack of colony formation in FS090 correlates
well with its lack of tumorigenicity.
Vascular supply is also a major factor in tumorigenesis
[34]. Studies have demonstrated that microvascular den-
sity increases with chondrosarcoma grade [35,36], and
new anti-angiogenic agents are being used successfully in
the experimental animal to reduce vessel development
and also chondrosarcoma progression [9]. Therefore, we
aimed to determine the influence of angiogenic-related
factors produced by JJ012 and FS090 to explain differ-
ences observed in tumorigenesis. VEGF is well-known to
stimulate migration of endothelial cells, and is a key pro-
tein in chondrosarcoma angiogenesis and its expression
correlates with higher grade chondrosarcoma [35]. When
medium from JJ012 or FS090 cells was used to suspend
HMEC-1 with underlying Matrigel, tube formation was
significantly lower in number for the FS090 medium-
treated wells. This corresponded with virtually undetect-
able VEGF protein levels when western blotting was per-
formed for FS090, while JJ012 was VEGF-positive. Lin et
al [37] examined VEGF gene expression in both these cell
lines and actually found higher VEGF gene expression in
FS090, although when exposed to 24 hours of hypoxia,
JJ012 produced a greater increase in VEGF gene expres-
sion than FS090. Furthermore, the level of HIF-1α in
JJ012 was somewhat greater than for FS090 under
hypoxic conditions [37]. Hypoxic conditions are more
likely in JJ012 cell culture given the higher proliferation
rate and closely packed nature which the cells display on
culture plates. This may translate to more expressed
VEGF protein demonstrated by this study.
One tumour suppressor with anti-angiogenic activity,
via inhibition of gelatinases [18] and possibly also via
inhibition of VEGF [19], is reversion-inducing, cysteine-
rich protein with kazal motifs (RECK) [18,38]. This pro-
tein could only be detected in FS090 on western blotting
(perhaps related to chromosome 9 preservation), and
RECK was associated with absent MMP-9, which fits
RECK's role as an MMP-9 inhibitor [38]. By contrast,
JJ012, being a more aggressive cell line and having a
known chromosome 9 monosomy, did not produce
RECK, potentially leaving MMP-9 expression unchecked.
These differences would further increase the tumorigenic
potential of JJ012.
While in vitro studies demonstrated higher potential
for tumour formation in the JJ012 cell line versus FS090,
we decided to pursue investigation of both cell lines in
vivo because of the value in having models with contrast-
ing tumour grades. Both inoculation approaches,
periosteal and intratibial/intramedullary, were used
because chondrosarcoma arises in both sites clinically,
although an intramedullary location is the most common.
Two different approaches were hoped to maximise suc-
cess of tumour growth and allow a comparison of growth
patterns and progression according to anatomical loca-
tion.
No tumour formation was observed for limbs injected
with FS090. Although this was consistent with in vitro
findings, it was surprising that FS090 did not grow even
in the periosteal location, which provided a very condu-
cive growth environment for JJ012. The FS090 cell line is
certainly not as aggressive as JJ012, but it does possess an
ability to invade Matrigel and stimulate angiogenesis,
which are key elements of tumorigenesis. A lack of
tumour growth in the nude mouse may relate to the com-
bination of a differentiated morphology, a preserved
chromosomal compliment, undetectable gelatinases and
VEGF, and reduced osteoclastogenesis.
The reason for differences in osteoclastogenesis
between the two cell lines is not fully defined but the
presence of VEGF and MMP-9 in JJ012, and the lack of
these proteins in FS090 provide a starting point. MMP-9
is known to play a prominent role in osteoclast recruit-
ment [39], and also migration [40]. Also, because RECK is
an inhibitor of MMP-9, the absence of RECK in JJ012 may
contribute to a higher potential for MMP-9 mediated
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tion by increasing osteoclast cell survival and bone
resorption capacity [41], and can act as a substitute for
M-CSF in stimulating osteoclastogenesis [42].
In regard to JJ012 tumorigenesis, the more rapid
growth and progression of the periosteal tumour site is
likely to relate to the developing tumour being uncon-
fined by rigid bone, and perhaps a more direct vascular
supply from the adjacent femoral vessels compared with
intratibial implantation. Periosteum is known to have a
very dense capillary network, even more so than skin and
skeletal muscle, and with relatively large diameter capil-
laries [43]. This network contributes 80% of the arterial
blood supply to the bone cortex as observed in guinea pig
long bones [44]. On the other hand, the endosteal portion
of the metaphysis (site of JJ012 intratibial injection)
receives its arterial supply predominantly from one nutri-
ent artery, which then divides within the bone, and from
metaphyseal end-arteries which usually do not anasto-
mose [45]. Sparing of the growth plate was noted for both
implantation sites, and this anatomical structure has been
shown to be a barrier to sarcoma invasion due to the
presence of anti-angiogenic factors like PEDF [46].
Despite more rapid periosteal growth experimentally,
the clinical comparison of periosteal and intramedullary
chondrosarcoma is quite the opposite. Clinically,
periosteal chondrosarcoma is a more indolent neoplasm,
of low histological grade, low rate of lung metastases [47],
and has an overall 5 year survival of 83% [48]. The dis-
crepancy with our more aggressive model of periosteal
chondrosarcoma clearly lies in the use of an aggressive/
less-differentiated cell line (JJ012). In the more rare
instances where clinical periosteal chondrosarcomas have
demonstrated higher grade histology, the progression of
these tumours has been suitably more aggressive with
50% of intermediate grade tumours resulting in metasta-
ses versus 6% of low grade tumours [48].
Although low grade orthotopic chondrosarcoma mod-
els should be sought, given the greater prevalence of low
grade disease, it is equally advantageous to investigate
novel agents in intermediate to high grade chondrosar-
coma because this spectrum of disease has the most
impact on patient survival, while still comprising over a
third of all cases [49]. As the periosteal implantation
more consistently produces lung metastases it should
provide a suitable means to assess novel agents predicted
to inhibit aspects of the metastatic cascade. For pharma-
ceutical drug R+D, tumour models that grow within 2-3
months, require non-exacting skills for model establish-
ment, incorporate both primary and secondary tumours,
and are viable/palpable non-invasively, present as the best
to use. The JJ012 periosteal model fits these criteria. The
intratibial model, on the other hand, may facilitate char-
acterisation of interactions between chondrosarcoma and
bone, and the influence of molecular agents on local
tumour progression.
Conclusion
The intratibial and periosteal models of chondrosarcoma
described provide a useful representation of high grade
chondrosarcoma in orthotopic sites. These models pro-
vide an assessment platform for future candidate thera-
pies in chondrosarcoma. Furthermore, the models will
facilitate more in-depth investigation into the biology of
chondrosarcoma, particularly in terms of its interaction
with bone.
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